The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5527-5531

  Zheng, You Bing ^a,b   Zhao, Wei ^a,b   Liu, Bing ^a,b   Lu, Li Gong ^a   He, Xu ^a   Huang, Jian Wen ^a   Li, Yong ^a   Hu, Bao Shan ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Neutrophil lymphocyte ratio; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE; SORAFENIB;

AGED; ARTICLE; BLOOD; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; LYMPHOCYTE; MALE; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; SURVIVAL RATE;

EID: 84887572063     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5527     Document Type: Article

References (31)

1. Abou-Alfa GK, Schwartz L, Ricci S, et al (2006). Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 24, 4293-300.
2. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2.
3. Carlomagno F, Anaganti S, Guida T, et al (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, 98, 326-34.
4. Chen TM, Lin CC, Huang PT, Wen CF (2012). Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol, 27, 553-61.
5. Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10, 25-34.
6. Chew V, Tow C, Teo M, et al (2010). Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol, 52, 370-9.
7. Cho JY, Paik YH, Lim HY, et al (2013). Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int, 33, 950-7.
8. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.
9. Ding PR, An X, Zhang RX, et al (2010). Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis, 25, 1427-33.
10. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55.
11. Gomez D, Farid S, Malik HZ, et al (2008). Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg, 32, 1757-62.
12. Halazun KJ, Hardy MA, Rana AA, et al (2009). Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg, 250, 141-51.
13. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
14. Hsu CH, Shen YC, Lin ZZ, et al (2010). Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol, 53, 126-31.
15. Hung HY, Chen JS, Yeh CY, et al (2011). Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis, 26, 1059-65.
16. Iavarone M, Cabibbo G, Piscaglia F, et al (2011). Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology, 54, 2055-63.
17. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res, 60, 184-90.
18. Kuang DM, Zhao Q, Wu Y, et al (2011). Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol, 54, 948-55.
19. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003). Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis, 6, 283-7.
20. Limaye AR, Clark V, Soldevila-Pico C, et al (2012). Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res, 43, 757-64.
21. Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90.
22. McDonald B, Spicer J, Giannais B, et al (2009). Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer, 125, 1298-305.
23. McNally ME, Martinez A, Khabiri H, et al (2013). Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Surg Oncol, 20, 923-8.
24. Minguez B, Lachenmayer A (2011). Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers, 31, 181-90.
25. Motomura T, Shirabe K, Mano Y, et al (2013). Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol, 58, 58-64.
26. Ohtani H (2007). Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun, 7, 4.
27. Prete SD, Montella L, Caraglia M, et al (2010). Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So LAR study. Cancer Chemother Pharmacol, 66, 837-44.
28. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T (1997). Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol, 15, 826-32.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16.
30. Vincenzi B, Santini D, Russo A, et al (2010). Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist, 15, 85-92.
31. Wilhelm S, Chien DS (2002). BAY 43-9006: preclinical data. Curr Pharm Des, 8, 2255-7.